The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Alnylam Pharmaceuticals's share price is R$75.36.
Alnylam Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was R$4.32. Hence, Alnylam Pharmaceuticals's PS Ratio for today is 17.46.
The historical rank and industry rank for Alnylam Pharmaceuticals's PS Ratio or its related term are showing as below:
BSP:A1LN34'
s PS Ratio Range Over the Past 10 Years
Min: 9.13 Med: 59.11 Max: 222.78
Current: 15.38
During the past 13 years, Alnylam Pharmaceuticals's highest PS Ratio was 222.78. The lowest was 9.13. And the median was 59.11.
BSP:A1LN34's PS Ratio is ranked worse than 61.18% of 1015
companies
in the Biotechnology industry
Industry Median: 8.73
vs BSP:A1LN34: 15.38
Alnylam Pharmaceuticals Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Alnylam Pharmaceuticals was 21.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 50.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 75.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 40.90% per year.
During the past 13 years, Alnylam Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 112.30% per year. The lowest was -31.50% per year. And the median was 31.90% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Alnylam Pharmaceuticals's PS Ratio
For the Biotechnology subindustry, Alnylam Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alnylam Pharmaceuticals's PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where Alnylam Pharmaceuticals's PS Ratio falls into.
Alnylam Pharmaceuticals PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Alnylam Pharmaceuticals's Share Price of today is R$75.36. Alnylam Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$4.32.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Alnylam Pharmaceuticals (BSP:A1LN34) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Alnylam Pharmaceuticals PS Ratio Related Terms
Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BSP:A1LN34 has been successfully added to your 